Where GLP-1 comes from
Glucagon-like peptide-1 is an incretin hormone secreted by enteroendocrine L cells, which are most densely concentrated in the distal small intestine (ileum) and colon. Nutrient contact, especially glucose, fatty acids, and amino acids in the gut lumen, triggers release. GLP-1 is cleaved from the proglucagon precursor, the same gene that yields glucagon in pancreatic alpha cells through alternative tissue-specific processing.
What GLP-1 does downstream
Once released, GLP-1 acts on pancreatic beta cells to amplify glucose-dependent insulin secretion, meaning it raises insulin chiefly when blood glucose is already elevated. It also suppresses glucagon from alpha cells, slows gastric emptying, and signals satiety in the hypothalamus and brainstem. Native GLP-1 is degraded within minutes by the enzyme DPP-4, which is why its half-life in circulation is very short.
GLP-1 receptor agonists such as semaglutide and liraglutide are engineered to resist DPP-4 cleavage, extending the half-life to hours or days and sustaining these effects. This information is educational and not medical advice; treatment decisions about incretin-based therapies should be made with a clinician.